Cutting Edge: Regulatory T Cells from Lung Cancer Patients Directly Inhibit Autologous T Cell Proliferation1

By E. Woo, H. Yeh, C. Chu, K. Schlienger, R. Carroll, J. Riley, L. Kaiser, C. June. Journal of Immunology, 2002

756 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/026669ed3e8bbc73be34377f0223524010bf53e2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. Lisa M. Coussens
2. D. DeNardo
3. E. Shevach
4. C. Zappa
5. Marc Beyer
6. J. Barreto
7. Di Zhao
8. D. Tawfik

In Oncology

1. D. DeNardo
2. Lisa M. Coussens
3. C. Zappa
4. E. Shevach
5. Shaker A. Mousa
6. Joachim L. Schultze
7. R. DePinho
8. A. Mantovani

Citations in the corpus

• The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. (2006, background): “, 2004) and in the tumor microenvironment of other solid tumors, such as pancreatic, colon, lung, and breast adenocarcinomas (Liyanage et al., 2002; Woo et al., 2002).”
• Developmental Stage, Phenotype, and Migration Distinguish Naive- and Effector/Memory-like CD4+ Regulatory T Cells (2004, background): “It is tempting to speculate that those T cells with suppressive potential that could be isolated from effector sites such as synovial fluid of rheumatoid arthritis patients (45), lung tumors (46), transplants (47), skin lesions of Leishmania major–infected mice (17), islets of Langerhans in a diabet”
• Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. (2004, background): “…whether suppressive activity of CD4 Treg cells could be reversed by exogenous IL-2, we added in the TILs of patients with cancer (Liyanage et al., 2002; Woo et al., 2002), but they provided no direct evidence600 IU/ml final concentration of IL-2 to the culture medium during the suppressive assay.”
• Regulatory T cells in cancer. (2006, result): “More important, Treg cells mediated potent inhibition of T cell proliferation.(67) Supporting this initial report, a larger study concluded that prevalence of CD4CD25 Treg cells is increased not only in the tumor microenvironment of patients with invasive breast or pancreas cancers but also in PB, s”
• Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. (2005, background): “However, they can suppress the activation and proliferation of other CD4 and CD8 T cells (13, 14).”
• Conversion of Peripheral CD4+CD25− Naive T Cells to CD4+CD25+ Regulatory T Cells by TGF-β Induction of Transcription Factor Foxp3 (2003, background): “Although not unanimous, increasing evidence has demonstrated that Treg produce/express higher levels of TGF- , which plays a significant role in immune regulation in vitro and in vivo (27, 29, 30, 36, 37).”
• Genetics and biology of prostate cancer (2018, background): “In many human tumor types, immunosuppressive FoxP3+ Tregs are present in the TME (Woo et al. 2002; Ormandy et al. 2005; Chaudhary and Elkord 2016) and suppress effector T-cell responses (Josefowicz et al. 2012).”